about
The detection, treatment, and biology of epithelial ovarian cancerHyaluronidase expression induces prostate tumor metastasis in an orthotopic mouse modelEGFR/HER-targeted therapeutics in ovarian cancerOvarian cancer biomarker discovery based on genomic approachesGenomic activation of the EGFR and HER2-neu genes in a significant proportion of invasive epithelial ovarian cancers.MicroRNA-7 inhibits tumor metastasis and reverses epithelial-mesenchymal transition through AKT/ERK1/2 inactivation by targeting EGFR in epithelial ovarian cancerRHBDD1 upregulates EGFR via the AP-1 pathway in colorectal cancer.Development of a multimarker assay for early detection of ovarian cancer.Antiproliferative effect of growth hormone-releasing hormone (GHRH) antagonist on ovarian cancer cells through the EGFR-Akt pathway.A new drug delivery method of bispecific ligand-directed toxins, which reduces toxicity and promotes efficacy in a model of orthotopic pancreatic cancer.Prognostic biomarkers in ovarian cancer.Proteomics and ovarian cancer: integrating proteomics information into clinical careThe coupling of epidermal growth factor receptor down regulation by 1alpha,25-dihydroxyvitamin D3 to the hormone-induced cell cycle arrest at the G1-S checkpoint in ovarian cancer cells.Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management.Dynamic modulation of phosphoprotein expression in ovarian cancer xenograft modelsThe OPCML tumor suppressor functions as a cell surface repressor-adaptor, negatively regulating receptor tyrosine kinases in epithelial ovarian cancer.In vivo breast cancer characterization imaging using two monoclonal antibodies activatably labeled with near infrared fluorophores.A distinct molecular profile associated with mucinous epithelial ovarian cancer.Id-I stimulates cell proliferation through activation of EGFR in ovarian cancer cellsMatrix metalloproteinase 9 is a mediator of epidermal growth factor-dependent e-cadherin loss in ovarian carcinoma cells.Priming with EGFR tyrosine kinase inhibitor and EGF sensitizes ovarian cancer cells to respond to chemotherapeutical drugs.3,4-dihydroxyphenyl acetic acid and (+)-epoxydon isolated from marine algae-derived microorganisms induce down regulation of epidermal growth factor activated mitogenic signaling cascade in Hela cells.Adult diffuse gliomas produce mRNA transcripts encoding EGFR isoforms lacking a tyrosine kinase domainActivated epidermal growth factor receptor in ovarian cancer.Nuclear expression of epidermal growth factor receptor is a novel prognostic value in patients with ovarian cancer.Identification of immunoreactive regions of homology between soluble epidermal growth factor receptor and α5-integrinA phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer.HE4 (WFDC2) gene overexpression promotes ovarian tumor growthTargeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges.Purification method directly influences effectiveness of an epidermal growth factor-coupled targeting agent for noninvasive tumor detection in mice.ERBB signaling in CTCs of ovarian cancer and glioblastoma.
P2860
Q21198791-A8682186-D4F0-4217-928C-106831AF610DQ22064565-F0518078-A56E-447D-A947-9E8C2261BBE4Q26863231-76F5D585-31B5-4CB0-BFC4-80D2C5107121Q27013687-71B445C7-6F34-4C65-96A7-2A09B1322763Q33313648-0DE881C2-21BE-429E-B886-346551D80076Q33590704-5672D891-DDAB-4543-82A4-0C0F3EA1B35DQ33648830-C5E40C00-A2C0-42A9-B3F6-FFEE2543D4F9Q33813724-29814C37-8C32-4387-BA9D-8FE1FC967405Q33939652-374B2D53-DAF7-4271-8220-B1FB1C744272Q34009357-48555C8C-374F-4B6C-8FCB-B51875020845Q34086636-E5DDBF2D-383F-4D23-B830-96CFF7B5FF11Q34126627-3C578C36-529B-4E07-BBE9-1252100F7CB7Q34949693-F6753C19-180E-455B-8024-0D12899D3032Q34977063-22751480-D88C-4288-89E1-C45A91633ECFQ35953034-1193C6A1-BCCE-4C80-968B-ED1FD4173581Q36041745-0464ED88-A5E4-40E7-B6E5-5BDB28766C4EQ36245602-1BD2FC00-715B-4BE5-B12A-514844448FBBQ36614490-36FE799E-054D-4503-9DA0-E4D7279FC034Q36695270-136EF5DD-D611-44A3-81C2-15E3B7EBC885Q36752057-550FB72F-17B0-49D4-998B-AD632887AA85Q36846821-157868B2-22D3-4876-8722-059E30D7B03BQ36905911-8A5A8FA7-6650-40AC-9DFE-D1DB64CB5914Q36923965-E4B72B40-A9BF-4340-912E-1B1252D0ABE0Q36981918-87F86E76-17AD-41D5-BE04-A875D2D25740Q37282661-A6A52A7E-9F72-43E4-831F-FCFE4FE3A396Q37391086-1E00CA0A-26FB-4AD7-AF8D-B8372416F25BQ37423291-EE934E79-3F80-4B73-871F-46A5B036B808Q37434141-361F533C-DD8C-4A6F-A539-BBA12348FE13Q37485865-0129FCA1-DC6F-4A5A-98E3-1DCF49113EA3Q40190596-FCD51DF1-6E9D-42A8-9921-078B25E43B48Q49236005-108650BA-3795-4F0E-BA5D-0399A134B7D9
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
EGF/ErbB receptor family in ovarian cancer.
@ast
EGF/ErbB receptor family in ovarian cancer.
@en
EGF/ErbB receptor family in ovarian cancer.
@nl
type
label
EGF/ErbB receptor family in ovarian cancer.
@ast
EGF/ErbB receptor family in ovarian cancer.
@en
EGF/ErbB receptor family in ovarian cancer.
@nl
prefLabel
EGF/ErbB receptor family in ovarian cancer.
@ast
EGF/ErbB receptor family in ovarian cancer.
@en
EGF/ErbB receptor family in ovarian cancer.
@nl
P2093
P1476
EGF/ErbB receptor family in ovarian cancer.
@en
P2093
Barrette BA
Boardman CH
Christensen TA
Faupel-Badger JM
Greenwood T
P304
P577
2002-01-01T00:00:00Z